Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Loar

Pediatrics Dublin, OH Medical Doctor

NPI 1639234073 CMS profile 209690

5110 Blazer Pkwy, Dublin, OH 43017

Open in the dashboard

General payments

$6,981

376 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Loar of Dublin, OH is reported in the CMS Open Payments database as having received $6,981 across 376 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $936 51
2024 General $1,200 65
2023 General $1,432 76
2022 General $1,232 59
2021 General $1,071 56
2020 General $258 11
2019 General $851 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Loar
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Michael Loar were reported at $936. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Michael Loar Pediatrics median Middle half National median
2019 $851 $86 $31–$183 $163
2020 $258 $49 $22–$110 $114
2021 $1,071 $68 $27–$158 $132
2022 $1,232 $77 $30–$173 $149
2023 $1,432 $88 $33–$190 $160
2024 $1,200 $94 $34–$206 $164
2025 $936 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Corium, Inc. $1,241 56 payments
  2. Tris Pharma Inc $1,165 73 payments
  3. GlaxoSmithKline, LLC. $705 31 payments
  4. Supernus Pharmaceuticals, Inc. $701 29 payments
  5. Neos Therapeutics, LP $676 50 payments
  6. Neurelis, Inc. $385 9 payments
  7. Ironshore Pharmaceuticals Inc. $275 23 payments
  8. Merck Sharp & Dohme Corporation $220 12 payments
  9. Seqirus USA Inc $187 9 payments
  10. Rhodes Pharmaceuticals L.P. $169 10 payments
  11. Other $1,255 74 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,981 376 payments
Products named General payments · program years 2019–2025
  1. Azstarys $1,241 56 payments
  2. BEXSERO $685 30 payments
  3. Dyanavel XR Adhd $594 56 payments
  4. QELBREE Psychology $451 20 payments
  5. Dyanavel XR Adhd $387 10 payments
  6. VALTOCO $385 9 payments
  7. Adzenys XR-ODT $360 26 payments
  8. COTEMPLA XR-ODT $349 27 payments
  9. Quillivant $306 4 payments
  10. Qelbree Viloxazine Hydrochloride $250 9 payments
  11. Other $3,167 191 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

16

Median for Pediatric Medicine: 38

Drug cost

$8,447

Median for Pediatric Medicine: $2,769

Branded share of claims

100%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zoloft Sertraline Hcl Brand 16 $8,447

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VALTOCO
  • Neurelis, Inc. $201
$201 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $177
$177 — —
Azstarys
  • Corium, Inc. $165
$165 — —
Dyanavel XR
  • Tris Pharma Inc $143
$143 — —
Adzenys XR-ODT
  • Neos Therapeutics, LP $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

376 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record